CD33 rs1803254: Understanding This Alzheimer's-Linked Variant
The rs1803254 variant is a genetic polymorphism located within the CD33 gene, which encodes a protein expressed on the surface of microglia, the brain's immune cells. Research indicates that this variant is statistically associated with the risk of developing late-onset Alzheimer's disease by influencing how these cells respond to neuroinflammation.
What each genotype means
Typical CD33 expression profile
This genotype represents the most common configuration for this variant. Research indicates that this variant influences how the CD33 gene is expressed and spliced in microglia, which are immune cells in the brain involved in Alzheimer's disease risk. This profile is considered the baseline for comparison in most genetic studies.
This is the most frequent genotype observed across most global populations.
Altered CD33 expression profile
Carrying one copy of the G allele may influence the splicing and expression levels of the CD33 protein in your microglia. Because CD33 plays a role in how these cells interact with amyloid-beta plaques, this variant is studied for its potential role in modulating Alzheimer's disease risk. Genetic risk is complex and multifactorial, so this result should not be viewed as a diagnostic indicator.
This heterozygous genotype is found in a significant portion of the population, with frequencies varying by ancestry.
Distinct CD33 expression profile
This genotype is associated with specific patterns of CD33 splicing in brain immune cells. Scientific literature suggests that variations in CD33 expression can affect the ability of microglia to clear cellular debris, which is a factor under investigation in Alzheimer's disease research. As with all genetic risk factors, this does not determine health outcomes and should be discussed in the context of your overall health history.
This genotype is less common than the C/C configuration but is present in diverse populations worldwide.
What is rs1803254?
The rs1803254 variant is a single nucleotide polymorphism (SNP) situated on chromosome 19 within the CD33 gene. In genetic terms, this variant represents a specific position in the DNA sequence where individuals may carry either a cytosine (C) or a guanine (G) nucleotide. Because it is located in a non-coding region of the gene, specifically a 3-prime untranslated region (UTR), it is thought to influence the regulation of the CD33 protein rather than changing the protein's structure directly. Scientists study this location because variations here can alter how much CD33 is produced or how the gene is spliced, which in turn affects the behavior of immune cells in the brain. It is one of several variants within the CD33 locus that researchers monitor to better understand the complex genetic architecture of neurodegenerative conditions.
The Role of the CD33 Gene
The CD33 gene provides instructions for making a transmembrane protein that acts as a receptor on the surface of myeloid cells, including microglia. Microglia are the primary immune cells of the central nervous system, responsible for clearing debris and responding to injury or infection. CD33 functions as an inhibitory receptor; when it binds to sialic acids, it triggers signaling pathways that dampen the immune response. In the context of Alzheimer's disease, this inhibitory function is critical. If CD33 activity is too high, it may prevent microglia from effectively clearing amyloid-beta plaques, which are a hallmark of the disease. Conversely, modulating CD33 expression is currently being investigated as a potential therapeutic strategy to enhance the brain's ability to manage these toxic protein accumulations and reduce overall neuroinflammation.
Research and Evidence Strength
The association between CD33 variants and Alzheimer's disease is supported by genome-wide association studies (GWAS). While rs1803254 is recognized as a relevant marker, the evidence for its specific impact is considered moderate, as it is often studied alongside other functional polymorphisms in the same gene, such as rs3865444. Research suggests that these variants collectively influence the risk of late-onset Alzheimer's disease by modulating microglial activation states. It is important to note that genetic associations are statistical in nature; they describe a correlation across large populations rather than a direct cause-and-effect relationship for any single individual. Because Alzheimer's disease is a multifactorial condition influenced by age, lifestyle, and many other genetic factors, the presence of a specific genotype at rs1803254 does not determine an individual's health outcome.
Population Frequency
The rs1803254 variant is considered a common polymorphism found across diverse global populations. Studies have observed varying minor allele frequencies depending on ancestral background, with some research noting differences in how the variant correlates with disease risk in North Han Chinese versus African American cohorts. Because it is a common variant, a significant portion of the general population carries at least one copy of the minor allele. This widespread distribution makes it a frequent subject of study in large-scale genetic research, as understanding its frequency helps scientists refine polygenic risk scores and better characterize the genetic landscape of neurodegenerative susceptibility across different ethnic groups.
What This Information Means for You
Learning about your genotype for rs1803254 provides insight into your genetic makeup, but it cannot be used to diagnose Alzheimer's disease or predict your personal risk with certainty. Genetic testing for such variants is primarily for educational or research purposes. Because Alzheimer's is complex and influenced by many factors, you should never use this information to make medical decisions or assume a specific health trajectory. If you have concerns about cognitive health or family history, the most appropriate step is to consult with a healthcare professional or a genetic counselor. They can provide context based on your full medical history and help you understand the limitations of genetic testing. Always prioritize evidence-based clinical assessments over individual genetic markers when evaluating your health.
How common is this variant?
The rs1803254 variant is a common polymorphism with a minor allele frequency that varies across different ancestral populations, typically ranging in the moderate frequency spectrum.
Frequently asked questions
Does having the G allele mean I will get Alzheimer's?
No. Genetic variants like rs1803254 are associated with statistical risk, not certainty. Many people with this variant never develop Alzheimer's, and many without it do.
Can I change my CD33 expression through diet?
There is currently no established scientific evidence that specific diets can directly modify CD33 expression in the brain. Always consult a doctor before making significant lifestyle changes based on genetic information.
Is there a test to see if my CD33 gene is working correctly?
Clinical testing for CD33 expression levels is not a standard diagnostic procedure. Genetic testing for this SNP is generally limited to research or ancestry-focused platforms.
How does CD33 relate to amyloid plaques?
CD33 acts as a brake on microglial cells. When CD33 is highly active, it may prevent these cells from effectively clearing amyloid-beta plaques, which are associated with Alzheimer's pathology.
Sources & further reading
Educational information only, last refreshed 9/26/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1803254?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CD33
This variant influences the splicing of CD33 and is associated with the efficacy of gemtuzumab ozogamicin therapy in acute myeloid leukemia.
This variant in the CD33 gene is associated with altered CD33 protein expression and efficacy of the leukemia drug gemtuzumab ozogamicin.
This variant in CD33 exon 2 modulates mRNA splicing, influencing the expression of a truncated isoform that is associated with both altered risk of Alzheimer's disease and clinical outcomes in AML patients treated with gemtuzumab-ozogamicin.